Disruption of plateletleukocyte interaction and increased levels of P-selectin as possible causes of resistance to acetylsalicylic acid in patients before and after coronary bypass surgery

Authors: Grinstein Yu.I., Kosinova A.A., Maltseva A.N., Shavrina E.O., Savchenko A.A., Subbotina T.N.

Company: 1 V.F. Voyno-Yasenetskiy Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
2 Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, “Research Institute of Medical Problems of the North” Krasnoyarsk, Russian Federation
3 Siberian Federal University, Krasnoyarsk, Russian Federation
4 Federal Siberian Research Clinical Center under Federal Medical and Biological Agency, Krasnoyarsk, Russian Federation

For correspondence:  Sign in or register.

Type:  Original articles

DOI: https://doi.org/10.24022/1997-3187-2023-17-2-237-246

For citation: Grinstein Yu.I., Kosinova A.A., Maltseva A.N., Shavrina E.O., Savchenko A.A., Subbotina T.N. Disruptionof platelet-leukocyte interaction and increased levels of Р-selectin as possible causes of resistance to acetylsalicylic acid in patients before and after coronary bypass surgery. Creative Cardiology. 2023; 17 (2): 237–46 (in Russ.). DOI: 10.24022/1997-3187-2023-17-2-237-246

Received / Accepted:  27.03.2023 / 26.06.2023

Keywords: acetylsalicylic acid clopidogrel aggregation platelets aortocoronary bypass

Subscribe 🔒



Objective. Studying the parameters of intercellular interaction: platelet-platelet, platelet-leukocyte; the level of expression of P-selectin in resistant and sensitive to acetylsalicylic acid (ASA) patients with coronary artery disease (CAD) before and after coronary bypass surgery (CABG).

Material and methods. 76 patients with functional class II–IV angina pectoris a day before CABG and on the 8th10th day after CABG without and with antiplatelet therapy accordingly underwent: clinical and biochemical labs, resistance to ASA, optical aggregatometry, flow cytometry. Resistance to ASA was determined at the level of platelet aggregation with arachidonic acid ≥20%. Flow cytometry was performed to isolate platelets (CD41), monocytes (CD14, CD16), determination the cell adhesion of platelets and the expression of P-selectin on platelets (CD62P).

Results. In the research 25 (32.9%) of patients were resistant to ASA. In patients sensitive to ASA the aggregates monocytes+platelets CD62P were higher on the 8th-10th day after CABG compared with those resistant to ASA (85.47 [50.34–95.86] vs. 43.90 [20.85–56.14], p=0.002). The time of general anesthesia positively correlated with platelet aggregation activity (ρ=0.507, р=0.000). Intercellular aggregates were significantly higher on the 8th10th day after CABG compared with the indicators before CABG (platelets+neutrophil, c.u. (10.90 [5.54–55.10] vs. 57.50 [15.85–137.00], p=0.000), platelet+neutrophil, % (19.24 [11.560–30.43] vs. 24.49 [12.72–48.08], p=0.002), platelet CD62P+neutrophil, % (70.51 [42.85–87.09] vs. 76.06 [66.02–92.40], p=0.014), platelet CD62P+monocyte, % (4.97 [0.96–20.02] vs. 8.25 [2.78–32.51], p=0.022)).

Conclusion. In patients after CABG intercellular interaction was increased, which may be due to the influence of surgery.


  1. Puchin’yan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.L. High residual platelet reactivity during dual antiplatelet therapy, detected by optical aggregometry, and the incidence of atherothrombotic complications after stenting of coronary arteries in patients with coronary heart disease in real clinical practice. Rational Pharmacotherapy in Cardiology. 2016; 12 (4): 385–90 (in Russ.). DOI: 10.20996/1819-6446-2016-12-4-385-390
  2. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 2007; 167 (15): 1593–9. DOI: 10.1001/archinte.167.15.1593
  3. Gremmel T., Michelson A.D., Frelinger A.L., Bhatt D.L. Novel aspects of antiplatelet therapy in cardiovascular disease. Res. Pract. Thromb. Haemost. 2018; 2 (3): 439–49. DOI: 10.1002/rth2.12115
  4. Pavlov O.V., Chepanov S.V., Selutin A.V., Selkov A.V. Platelet-leukocyte interactions: immunoregulatory role and pathophysiological relevance. Medical Immunology. 2022; 24 (5): 871–88 (in Russ.). DOI: 10.15789/1563-0625-PLI-2511
  5. Loguinova M., Pinegina N., Kogan V., Vagida M., Arakelyan A., Shpektor A. et al. Monocytes of different subsets in complexes with platelets in patients with myocardial infarction. Thromb. Haemost. 2018; 118 (11): 1969–81. DOI: 10.1055/s-0038-1673342
  6. Pluta K., Porębska K., Urbanowicz T., Gąsecka A., OlasińskaWiśniewska A., Targoński R. et al. Platelet-leucocyte aggregates as novel biomarkers in cardiovascular diseases. Biology (Basel). 2022; 11 (2): 224. DOI: 10.3390/biology11020224
  7. Allen N., Barrett T.J., Guo Y., Nardi M., Ramkhelawon B., Rockman C. B. et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. Atherosclerosis. 2019; 282: 11–8. DOI: 10.1016/j. atherosclerosis.2018.12.029
  8. Golukhova E.Z., Grigoryan M.V., Ryabinina M.N., Bulaeva N.I., Serebruany V.L. Body mass index and plasma p-selectin before coronary stenting predict high residual platelet reactivity at 6 months on dual antiplatelet therapy. Cardiology. 2018; 139 (2): 132–6. DOI: 10.1159/000485555
  9. Ivert T., Dalén M., Ander C., Stalesen R, Lordkipanidze M. Increased platelet reactivity and platelet-leukocyte aggregation 246 Creative Cardiology. 2023; 17 (2) DOI: 10.24022/1997-3187-2023-17-2-237-246
  10. Drohomirecka A., Iwaszko A., Walski T. Pliszczak-Król A., Wąż G., Graczyk S. et al. Low-level light therapy reduces platelet destruction during extracorporeal circulation. Sci. Rep. 2018; 8: 16963. DOI: 10.1038/s41598-018-35311-9
  11. Romanyuk S.V., Vitkovsky Yu.A. Lymphocytic-platelet adhesion and platelet aggregation in patients with stable angina and acute coronary syndrome. Zabaikalsky Medical Bulletin. 2014; 4: 59–65 (in Russ.).
  12. Song C., Wu G., Chang S., Bie L. Plasma P-selectin level is associated with severity of coronary heart disease in Chinese Han population. J. Int. Med. Res. 2020; 48 (6): 300060519896437. DOI: 10.1177/0300060519896437
  13. Floyd C.N., Ferro A. Mechanisms of aspirin resistance. Pharmacol. Ther. 2014; 141: 69–78.
  14. Samir A., Gandreti N., Madhere M., Khan A., Brown M., Loomba V. Anti-inflammatory effects of propofol during cardiopulmonary bypass: a pilot study. Ann. Card. Anaesth. 2015; 18 (4): 495–501. DOI: 10.4103/0971-9784.166451
  15. Kuczyńska K., Boncler M. Emerging role of fentanyl in antiplatelet therapy. J. Cardiovasc. Pharmacol. 2020; 76 (3): 267–75. DOI: 10.1097/FJC.0000000000000880

About Authors

  • Yuriy I. Grinshtein, Dr. Med. Sci., Professor, Chief of Chair; ORCID
  • Aleksandra A. Kosinova, Cand. Med. Sci., Assistant; ORCID
  • Anna N. Maltseva, Postgraduate; ORCID
  • Ekaterina O. Shavrina, Laboratory Assistant-Researcher; ORCID
  • Andrey A. Savchenko, Dr. Med. Sci., Professor, Head of Laboratory; ORCID
  • Tatyana N. Subbotina, Dr. Biol. Sci., Associate Professor of the Department of Medical Biology, Head of Laboratory; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery